Patent 10092636 was granted and assigned to Pfizer Limited on October, 2018 by the United States Patent and Trademark Office.
The present disclosure provides (a) vectors comprising a multi-antigen construct encoding two, three, or more immunogenic PAA polypeptides; (b) compositions comprising the vectors, (c) methods relating to uses of the vectors and compositions for eliciting an immune response or for treating prostate cancers.